These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 12669026

  • 1. Targeting the CREB pathway for memory enhancers.
    Tully T, Bourtchouladze R, Scott R, Tallman J.
    Nat Rev Drug Discov; 2003 Apr; 2(4):267-77. PubMed ID: 12669026
    [Abstract] [Full Text] [Related]

  • 2. Potential therapeutic targets in the NF-kappaB pathway for Alzheimer's disease.
    Collister KA, Albensi BC.
    Drug News Perspect; 2005 Dec; 18(10):623-9. PubMed ID: 16491164
    [Abstract] [Full Text] [Related]

  • 3. Prospects of memory-modifying drugs that target the CREB pathway.
    Jackson T, Ramaswami M.
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):712-9. PubMed ID: 14579521
    [Abstract] [Full Text] [Related]

  • 4. Simvastatin enhances learning and memory independent of amyloid load in mice.
    Li L, Cao D, Kim H, Lester R, Fukuchi K.
    Ann Neurol; 2006 Dec; 60(6):729-39. PubMed ID: 17192930
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Memories are made of this: the genetic basis of memory.
    Fletcher L.
    Mol Med Today; 1997 Oct; 3(10):429-34. PubMed ID: 9358469
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers.
    Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, Walsh DM, Selkoe DJ.
    Ann Neurol; 2006 Dec; 60(6):668-76. PubMed ID: 17192927
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The expanding role of BDNF: a therapeutic target for Alzheimer's disease?
    Fumagalli F, Racagni G, Riva MA.
    Pharmacogenomics J; 2006 Dec; 6(1):8-15. PubMed ID: 16314887
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease.
    Feng Z, Chang Y, Cheng Y, Zhang BL, Qu ZW, Qin C, Zhang JT.
    J Pineal Res; 2004 Sep; 37(2):129-36. PubMed ID: 15298672
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model.
    Ostrovskaya RU, Gruden MA, Bobkova NA, Sewell RD, Gudasheva TA, Samokhin AN, Seredinin SB, Noppe W, Sherstnev VV, Morozova-Roche LA.
    J Psychopharmacol; 2007 Aug; 21(6):611-9. PubMed ID: 17092975
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
    Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR, Shippy D, Tan J.
    Neuroscience; 2006 Nov 03; 142(4):941-52. PubMed ID: 16938404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.